- Educatie
- Bron: Campus Sanofi
- 13 dec 2024
The Hematology Podcast - Season 4
Welcome to The Hematology Podcast, your source for the latest insights into hematology and rare blood disorders. This podcast covers cutting-edge research, clinical advancements, and real-world cases tailored for healthcare professionals. Each episode offers expert perspectives on evolving therapies and best practices, helping you stay informed and improve patient outcomes. Whether you're focused on research or clinical practice, The Hematology Podcast is designed to keep you at the forefront of the field, transforming your approach to hematology.
In this episode of The Hematology Podcast, we will delve into the complex world of thrombotic microangiopathy, or TMA. This condition encompasses a group of disorders characterized by small blood clots forming in the smallest blood vessels, leading to various complications. Diagnosing TMA can be particularly challenging due to its overlapping symptoms with other conditions and the need for specialized tests.
In today’s episode, we have the honor of welcoming Professor Riitta Lassila to the studio. Professor Lassila is a renowned expert in hematology with extensive experience in researching and treating TMA. She currently serves at the Helsinki University Hospital in Finland, where she leads the Hemostasis and Thrombosis Research Unit. Her groundbreaking work has significantly advanced our understanding of TMA and its management.
Expert guest
Riitta Lassila
Professor of Coagulation Medicine
In this episode, we dive into the fascinating world of liquid biopsy-derived DNA as a revolutionary tool for comprehensive mutation profiling in multiple myeloma. This innovative approach offers a non-invasive way to analyze genetic alterations, potentially transforming how we diagnose and monitor this complex hematological cancer. Join us as we explore the promises and challenges of using liquid biopsies to decode the genetic landscape of multiple myeloma and its implications for personalized medicine.
We have the pleasure of welcoming Dr. Wouter De Brouwer from Belgium to our studio. Dr. De Brouwer is a hematologist in training and PhD student at the hematology and immunology research group (HEIM) from the faculty of Brussels health campus, with a special interest in genomic profiling in hematological malignancies. Join us as Dr. De Brouwer sheds light on the potential of liquid biopsies to revolutionize personalized medicine and improve patient outcomes.
Expert guest
Riitta Lassila
Professor of Coagulation Medicine
In this episode of The Hematology Podcast, we will delve into the complex world of thrombotic microangiopathy, or TMA. This condition encompasses a group of disorders characterized by small blood clots forming in the smallest blood vessels, leading to various complications. Diagnosing TMA can be particularly challenging due to its overlapping symptoms with other conditions and the need for specialized tests.
In today’s episode, we have the honor of welcoming Professor Riitta Lassila to the studio. Professor Lassila is a renowned expert in hematology with extensive experience in researching and treating TMA. She currently serves at the Helsinki University Hospital in Finland, where she leads the Hemostasis and Thrombosis Research Unit. Her groundbreaking work has significantly advanced our understanding of TMA and its management.
Expert guest
Riitta Lassila
Professor of Coagulation Medicine
In this episode, we dive into the fascinating world of liquid biopsy-derived DNA as a revolutionary tool for comprehensive mutation profiling in multiple myeloma. This innovative approach offers a non-invasive way to analyze genetic alterations, potentially transforming how we diagnose and monitor this complex hematological cancer. Join us as we explore the promises and challenges of using liquid biopsies to decode the genetic landscape of multiple myeloma and its implications for personalized medicine.
We have the pleasure of welcoming Dr. Wouter De Brouwer from Belgium to our studio. Dr. De Brouwer is a hematologist in training and PhD student at the hematology and immunology research group (HEIM) from the faculty of Brussels health campus, with a special interest in genomic profiling in hematological malignancies. Join us as Dr. De Brouwer sheds light on the potential of liquid biopsies to revolutionize personalized medicine and improve patient outcomes.
Expert guest
Riitta Lassila
Professor of Coagulation Medicine
In this episode, we focus on Thalassemia major, a severe form of the disease. In a previous episode, we discussed Thalassemia minor and intermedia with Professor Dr. Bart Biemond from Amsterdam UMC. Now, we will delve deeper into the challenges and treatments associated with Thalassemia major. Prof. Biemond is still with us to share his expertise.
Professor Bart Biemond is a hematologist at the Amsterdam UMC in The Netherlands. Bart is head of the Hemoglobinopathy Expert Center and an active member of the medical advisory boards of the national patient associations.
Expert guest
Bart Biemond
Professor
Hematologist
Amsterdam UMC in The Netherlands
Acute myeloid leukemia (AML) is a hematopoietic stem cell-derived myeloid malignancy characterized by manifold genetic aberrations and poor overall survival. Standard treatment for newly diagnosed fit AML patients is intensive chemotherapy. Relapse is, however, a challenge in more than 40% of AML patients. AML is also a disease with a large degree of individual heterogeneity, which creates challenges both for diagnostics and for developing targeted treatment options.
Our guest is Björn Gjertsen, professor of hematology at the University of Bergen, Norway. Björn is also part of Centre for Cancer Biomarkers, CCBIO, and founding member and chair of the Nordic AML group and member of HOVON AML International Steering Group. He has extensive experience in treating AML, in clinical and translational research of AML, including very exciting newly published data on how single cell signalling profiling may help to detect responders and non-responders early in the treatment.
Expert guest
Björn Gjertsen
Professor of hematology
University of Bergen, Norway
In this episode, we focus on Thalassemia major, a severe form of the disease. In a previous episode, we discussed Thalassemia minor and intermedia with Professor Dr. Bart Biemond from Amsterdam UMC. Now, we will delve deeper into the challenges and treatments associated with Thalassemia major. Prof. Biemond is still with us to share his expertise.
Professor Bart Biemond is a hematologist at the Amsterdam UMC in The Netherlands. Bart is head of the Hemoglobinopathy Expert Center and an active member of the medical advisory boards of the national patient associations.
Expert guest
Bart Biemond
Professor
Hematologist
Amsterdam UMC in The Netherlands
Acute myeloid leukemia (AML) is a hematopoietic stem cell-derived myeloid malignancy characterized by manifold genetic aberrations and poor overall survival. Standard treatment for newly diagnosed fit AML patients is intensive chemotherapy. Relapse is, however, a challenge in more than 40% of AML patients. AML is also a disease with a large degree of individual heterogeneity, which creates challenges both for diagnostics and for developing targeted treatment options.
Our guest is Björn Gjertsen, professor of hematology at the University of Bergen, Norway. Björn is also part of Centre for Cancer Biomarkers, CCBIO, and founding member and chair of the Nordic AML group and member of HOVON AML International Steering Group. He has extensive experience in treating AML, in clinical and translational research of AML, including very exciting newly published data on how single cell signalling profiling may help to detect responders and non-responders early in the treatment.
Expert guest
Björn Gjertsen
Professor of hematology
University of Bergen, Norway
Smoldering multiple myeloma (SMM) is an intermediate condition that lies between Monoclonal gammopathy of undetermined significance (MGUS) and active multiple myeloma along the spectrum of clonal plasma cell proliferative disorders. Smoldering multiple myeloma may take years to become active multiple myeloma. In some cases, people who have this condition never develop active multiple myeloma.
In this episode we have the pleasure of having the Norwegian haematologist Fredrik Schjesvold with us. Fredrik is the founder and leader of Oslo Myeloma Center at Oslo University Hospital. Fredrik is an international expert on Multiple Myeloma in charge of one of Europe’s largest centres for clinical research in this disease. He is also chairman of the Nordic Myeloma Study Group and leads the Norwegian Myeloma Group. Besides he is member of the International Myeloma Working Group, and board member of the European Myeloma network (EMN).
Expert guest
Fredrik Schjesvold
Hematologist
Leader of Oslo Myeloma Center at Oslo University Hospital
Thalassemia is a hereditary blood disorder, in which the synthesis of hemoglobin chains is impaired. Consequently, people with thalassemia minor may have slight to severe anemia which usually does not cause any problems. Thalassemia major in contrast is a severe disorder with need of transfusion and complications with iron overload. In this episode we will mainly discuss thalassemia minor and intermedia.
Our guest today Professor Bart Biemond is a hematologist at the Amsterdam UMC in The Netherlands. Bart is head of the Hemoglobinopathy Expert Center and an active member of the medical advisory boards of the national patient associations. Today, Bart will tell us more about thalassemia, its clinical implications and developments in research which implicate patients today and in the future.
Expert guest
Bart Biemond
Professor
Hematologist
Amsterdam UMC in The Netherlands
Smoldering multiple myeloma (SMM) is an intermediate condition that lies between Monoclonal gammopathy of undetermined significance (MGUS) and active multiple myeloma along the spectrum of clonal plasma cell proliferative disorders. Smoldering multiple myeloma may take years to become active multiple myeloma. In some cases, people who have this condition never develop active multiple myeloma.
In this episode we have the pleasure of having the Norwegian haematologist Fredrik Schjesvold with us. Fredrik is the founder and leader of Oslo Myeloma Center at Oslo University Hospital. Fredrik is an international expert on Multiple Myeloma in charge of one of Europe’s largest centres for clinical research in this disease. He is also chairman of the Nordic Myeloma Study Group and leads the Norwegian Myeloma Group. Besides he is member of the International Myeloma Working Group, and board member of the European Myeloma network (EMN).
Expert guest
Fredrik Schjesvold
Hematologist
Leader of Oslo Myeloma Center at Oslo University Hospital
Thalassemia is a hereditary blood disorder, in which the synthesis of hemoglobin chains is impaired. Consequently, people with thalassemia minor may have slight to severe anemia which usually does not cause any problems. Thalassemia major in contrast is a severe disorder with need of transfusion and complications with iron overload. In this episode we will mainly discuss thalassemia minor and intermedia.
Our guest today Professor Bart Biemond is a hematologist at the Amsterdam UMC in The Netherlands. Bart is head of the Hemoglobinopathy Expert Center and an active member of the medical advisory boards of the national patient associations. Today, Bart will tell us more about thalassemia, its clinical implications and developments in research which implicate patients today and in the future.
Expert guest
Bart Biemond
Professor
Hematologist
Amsterdam UMC in The Netherlands
Get to know the host
In each episode, Dr. Mats Merup leads the interviews with the respective experts, providing a deep dive into the clinical, theoretical and practical aspects of the hematological field.
Associate professor Mats Merup, MD PhD (host)
Hematologist
Stockholm, Sweden
Mats Merup is an experienced clinical hematologist with an MD and PhD, specializing in malignant lymphomas and myeloproliferative disorders. He currently works in the clinical setting and has contributed to 50 published research publications as a clinical researcher.
Other channels to subscribe
The Hematology Podcast
Don’t miss the next episode, go to your favorite player and subscribe to the podcast
For additional insights and resources in hematology, refer to the following sites:
Educational programs for healthcare professionals
Educational programs for healthcare professionals
Neem contact op
MAT-BE-2401125 - 1.0 - 12/2024